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• Head and neck squamous cell carcinomas (HNSCCs) have remained 
one of the common and lethal cancers around the world.
• HNSCC rapidly spread via the lymphatics system, leading to a higher 
percentage of initial late-stage diagnoses and poor prognoses for 
patients. 
• CBX5 is downregulated highly metastatic breast cancers and may 
repress metastatic phenotypes 
• It is unclear what role is may have in HNSCC, or which specific functions 
of CBX5 drive its antimetastatic role. 
• We aim to map molecular changes to phenotypic expression in order to 
provide better diagnostic prognoses for different HNSCC cell types as 
well as possible pharmacologic targets for treatment. 
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SUMMARY
REGIONAL METASTASIS SIGNIFICANTLY DECREASES SURVIVAL AND IS
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Figure 5. Induction of the V22M point mutation interrupts CBX5’s ability to recognize the 
heterochromatin and bind to it. V22M-1 also had an additional unplanned mutation 
resulting in a frameshift and resultant total knockdown of CBX5 expression which 
fortuitously can be used as a negative control.







Disrupts CBX5 ligand binding
CBX5 GATEWAY CLONING
Figure 6. After early restriction digests showed a failed attempt to introduce I165E 
mutations we proceeded to only clone our V22M and W174A mutants to send for 
sequencing. In a preliminary restriction digest all 4 V22M mutants had correct 
lengths, and three W174A mutants were the correct length. These 7 were then sent 
for genetic sequencing to verify the correct mutations were present 
Figure 1. HNSCC rates are on the decline overall as are many cancers, however, the 
survivability of HNSCC has not significantly changed over time unlike other cancer 
subtypes. 
HYPOTHESIS: Heterochromatin binding by CBX5, but not 
dimerization or ligand activation, is necessary to suppress 






















Figure 2. Comparison of 
angiolymphatic invasion between 
N0- and N0+ patients. The 
clinical significance suggests that 
the genes that control the 
vascularity of tumors may be the 
strongest candidates for 
biomarker diagnosis in primary 
HNSCC tumors. 
CBX5 IS DOWNREGULATED IN AGGRESSIVE HNSCC 
Figure 3. CD31 staining of blood vessels of HNSCC primary tumors in mice, which 
helped determine which HNSCC metastatic cell lines were vascular and avascular.
















Figure 4. The CAL27 
and UMSCC17B cell 
lines are metastatic 
vascular and appear 
to have lower 
constitutive expression 
of CBX5 than the 
HN12, and HN6 lines 
which are metastatic 
avascular
• Metastatic vascular
• Metastatic avascular
